Merck Life Science in India has signed a Memorandum of Understanding (MoU) with Aragen, focusing on enhancing the supply of equipment and technologies for monoclonal antibody (mAb) manufacturing and process development. This collaboration aims to streamline the clinical-to-commercial process and support biotechnology startups in the country. The MoU was signed by Aditya Sharma from Merck and Subodh Deshmukh from Aragen, highlighting a mutual commitment to advancing drug discovery and innovative therapies. Merck's partnership with Aragen is expected to significantly expedite the development of novel modalities and mAbs. Both companies aim to leverage this alliance to foster early-stage R&D in India's growing life sciences sector.